Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/19377
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMrkalić, Emina-
dc.contributor.authorJelic, Ratomir-
dc.contributor.authorStojanović, Stefan-
dc.contributor.authorSovrlic, Miroslav-
dc.date.accessioned2023-11-09T12:47:28Z-
dc.date.available2023-11-09T12:47:28Z-
dc.date.issued2020-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/19377-
dc.description.abstractSerum albumin (HSA) is the most abundant carrier protein present in the circulatory system. The drug-serum albumin interaction plays a dominant role in the metabolism of drugs, its distribution, free concentration, and efficacy. Also, numerous exogenous and endogenous compounds bind to serum albumin as well alkaloids and flavonoids. Flavonoids belong to a group of phenolic compounds found in fruits and vegetables. Olanzapine (OLZ) is an atypical antipsychotic drug is widely used for the treatment of schizophrenia, bipolar disorder, and related psychiatric disorders. The aim of this study was to investigate the binding properties of OLZ to HSA and its competitive binding to HSA with flavonoids - diosmin (DIO), quercetin (QUE) and catechin (CAT) under the physiological conditions by fluorescence and absorption spectroscopy. Results of fluorescence experiments suggest that OLZ quench the fluorescence of HSA through the mixed quenching mechanism and non-radiation energy transferring because of the HSA–OLZ complex formation. OLZ spontaneously bind in the site I on HSA, and according to thermodynamic parameters, the reaction was spontaneous and mainly driven by hydrogen bonds and van der Waals interactions. The presence of DIO and CAT decreased binding affinity between OLZ and HSA which indicates that they could compete against OLZ in the site I. Contrary, in the presence of QUE the binding affinity of the HSA-OLZ system enhanced, which may be explained by conformational changes in HSA (non-competitive interference). This study may provide a better understanding of OLZ pharmacokinetics and illustrate drug-drug interactions.en_US
dc.language.isoenen_US
dc.subjectcompetitive bindingen_US
dc.subjectflavonoidsen_US
dc.subjectfluorescenceen_US
dc.subjecthuman serum albuminen_US
dc.subjectolanzapineen_US
dc.titleInteraction between olanzapine and human serum albumin and effect of flavonoids on the binding: A spectroscopic studyen_US
dc.typeconferenceObjecten_US
dc.description.versionPublisheden_US
dc.identifier.doi10.3390/ECMC2020-07480en_US
dc.relation.conference6th International Electronic Conference on Medicinal Chemistryen_US
dc.type.versionPublishedVersionen_US
Appears in Collections:Institute for Information Technologies, Kragujevac

Page views(s)

21

Downloads(s)

4



Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.